Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 6, 2007, Pages 307-313

  Bergman, Arthur ^a   Mistry, Goutam C ^a   Luo, Wen Lin ^a   Liu, Q ^a   Stone, Julie ^a   Wang, Amy ^a,c   Zeng, Wei ^a   Chen, Li ^a   Dilzer, Stacy ^b   Lasseter, Kenneth ^b   Herman, Gary A ^a   Wagner, John A ^a   Krishna, Rajesh ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PharmaNet Development Group Inc   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Dose proportionality; Final market image; Sitagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; SITAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; URINALYSIS; VITAL SIGN; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD26; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; TABLETS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 34548850640     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.559     Document Type: Article

References (9)

1. Kim D, Wang L, Beconi M et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- alpyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-151.
2. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003, 12: 87-100.
3. Villhauer EB, Coppola GM, Hughes TW. DPP-4 inhibition and therapeutic potential. Annu Rep Med Chem 2001; 36: 191-200.
4. Herman G, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
5. Zeng W, Musson DG, Fisher AL, Wang AQ. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 1169-1175.
6. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
7. Stein PP. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Late-breaking clinical study presented at the 66th Annual Scientific Session of the American Diabetes Association, Washington, DC, 10-14 June 2006. http://webcasts.prous.com/ ada2006_CME/article. asp?AID-166&CLID=2&CID=YY (last accessed 12 October 2006)
8. Bergman A, Stevens C, Zhou C et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
9. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.